

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	Little Green Pharma Ltd
<b>ACN</b>	615 586 215

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Angus McDougall Caithness
<b>Date of last notice</b>	18 August 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Banquo Consulting Pty Ltd - Mr Caithness is a director
<b>Date of change</b>	7 March 2022
<b>No. of securities held prior to change</b>  <small>* previous notice of 864,789 omitted 46,153 shares acquired on 11 March 2021 from share purchase plan</small>  <small>** Options were previously held by Mr Caithness and transferred via off-market transaction to Banquo Consulting Pty Ltd</small>	<u>Direct</u> 910,942* Ordinary shares  333,334 Class C Performance Rights 333,333 Class D Performance Rights 333,333 Class E Performance Rights  <u>Indirect</u> 5,500,000 Ordinary shares  <small>**3,500,000 Options exercisable at 30 cents, expiring 28 February 2022</small> 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights
<b>Class</b>	Fully paid ordinary shares

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	4,000,000
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Exercise of 3,500,000 unlisted options at \$0.30 each.  Conversion of 500,000 total performance rights for nil consideration.
<b>No. of securities held after change</b>	<u>Direct*</u> 1,410,942 Ordinary shares  166,667 Class C Performance Rights 166,666 Class D Performance Rights 166,667 Class E Performance Rights  <u>Indirect</u> 9,000,000 Ordinary shares 500,000 Class F Performance Rights 500,000 Class G Performance Rights 500,000 Class H Performance Rights
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of 3,500,000 unlisted options at \$0.30 each. Conversion of 500,000 total performance rights for nil consideration.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.